Speaker Profile
Ph.D., CEO, BrainStorm Tx
Biography
Robert Fremeau brings more than 20 years of neuroscience drug-development experience across academia and industry. As a Scientific Director at Amgen and CSO at Vyant Bio, he helped advance more than 10 CNS programs into clinical development. Earlier in his career, he held faculty appointments at Duke University Medical Center and the University of California, San Francisco. He has authored more than 65 peer-reviewed publications (H-index 46) and is an inventor on numerous patents. As CEO of BrainStorm Therapeutics, he advances human-relevant approaches to CNS drug discovery and builds strategic partnerships.
Talk
Predicting Human Efficacy Before Clinical Trials
BrainStorm combines patient-derived brain organoids with multimodal AI to discover treatments for brain diseases. The platform measures phenotypes across genetic epilepsies and neurodegenerative disorders, then experimentally tests AI-prioritized targets. Its translational promise is demonstrated by a Rett syndrome program that advanced from organoid screening to an IND-cleared Phase 2 trial.
AI for Emerging Therapeutics Showcase:
BrainStorm Therapeutics
BrainStorm Therapeutics combines patient-derived human brain organoids with multimodal AI to discover and validate treatments for brain diseases. After advancing a Rett syndrome program from organoid screening to an IND-cleared Phase 2 trial, the company is applying its platform to rare genetic epilepsies, Parkinson’s disease, and Alzheimer’s disease.
Session Abstract – PMWC 2027 Silicon Valley
The PMWC 2027 AI for Emerging Therapeutics Showcase will provide a 15-30 minute time slot for selected companies to explore the transformative role of artificial intelligence in accelerating the discovery, development, and optimization of novel therapeutic modalities. From predictive algorithms for drug efficacy to real-time analysis in clinical trials, AI is revolutionizing the way we approach emerging therapies, including RNA-based treatments, gene editing, and personalized medicine. Industry leaders and experts will discuss AI-driven advancements, collaborative frameworks, and the challenges of integrating cutting-edge technologies into therapeutic innovation. Join us for an in-depth look at how AI is shaping the future of breakthrough therapeutics.
Davos of Precision Medicine
PMWC 2027 Program
January 27–29, 2027 · Santa Clara Convention Center
Swipe speakers · Tap a card for sessions →
In a few words.
PMWC is indeed The Davos of Biotech
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
